U.S. flag

An official website of the United States government

Skip to main page content
Active, not recruiting

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD) (COPDGene)

ClinicalTrials.gov ID NCT00608764
Sponsor Brigham and Women's Hospital
Information provided by Edwin K. Silverman, Brigham and Women's Hospital (Responsible Party)
Last Update Posted 2024-08-06
Bookmark

Study Overview

Brief Summary
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is often caused by cigarette smoking. The purpose of this study is to evaluate whether certain genetic factors predispose some smokers to develop COPD more than others.
Detailed Description

COPD is a disease in which the lung airways are damaged and partly obstructed, making it difficult to breathe. Millions of people in the United States have COPD, and it is the third leading cause of death in the United States. Symptoms include coughing, excess mucus production, shortness of breath, wheezing, and chest tightness. Emphysema and long-term bronchitis are the two most common manifestations of the disease. The most common risk factor for developing COPD is cigarette smoking; however, only 15% to 20% of smokers develop COPD in their lifetimes. It is not known why some smokers develop COPD and some do not, but certain genetic factors, combined with exposure to cigarette smoke, may increase the likelihood of developing COPD. This study will analyze DNA from current and former cigarette smokers to identify genetic factors and markers that may indicate a predisposition to developing COPD.

This study will enroll African-American and white cigarette smokers and former cigarette smokers both with and without COPD. Participants will attend one study visit during which they will complete questionnaires about lung symptoms, breathing difficulties, medical and family history, and quality of life. They will also undergo blood collection, a physical exam, lung function testing, and a walking test to measure endurance. Participants will undergo a high resolution computed tomography (CT) chest scan and a medical record review. Study researchers will contact participants up to four times a year for 15 years to collect follow-up medical information. Five-year, ten-year, and fifteen-year follow-up visits including a similar study protocol as the baseline visit will be performed on all available subjects.

Show less
Official Title
Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene)
Conditions
Pulmonary Disease, Chronic Obstructive
Emphysema
Bronchitis, Chronic
Other Study ID Numbers
  • 1428
  • 75N92023D00011-0-7 ( Other Identifier ) (OTHER: NHLBI)
    75N92023D00011-0-7 ( Other Identifier ) (OTHER: NHLBI)
  • Show 2 more study numbers
Study Start
2007-11
Primary Completion (Estimated)
2028-08
Study Completion (Estimated)
2028-08
Enrollment (Actual)
10718
Study Type
Observational

Contacts and Locations

This section provides contact details for people who can answer questions about joining this study, and information on where this study is taking place.

To learn more, please see the Contacts and Locations section in How to Read a Study Record(https://clinicaltrials.gov/study-basics/how-to-read-study-record#contacts-and-locations).

This study has 20 locations
United States
Alabama Locations
Birmingham, Alabama, United States, 35249

University of Alabama at Birmingham
California Locations
San Diego, California, United States, 92103

University of California at San Diego
Torrance, California, United States, 90502

Los Angeles Biomedical Research Institute
Colorado Locations
Denver, Colorado, United States, 80206

National Jewish Health
Georgia Locations
Atlanta, Georgia, United States, 30310

Morehouse School of Medicine
Iowa Locations
Iowa City, Iowa, United States, 52242

University of Iowa
Maryland Locations
Baltimore, Maryland, United States, 21224

Johns Hopkins University
Massachusetts Locations
Boston, Massachusetts, United States, 02115

Brigham and Women's Hospital
Worcester, Massachusetts, United States, 01608

Reliant Medical Group
Michigan Locations
Ann Arbor, Michigan, United States, 48105

Ann Arbor VA Medical Center
Ann Arbor, Michigan, United States, 48109

University of Michigan
Minnesota Locations
Minneapolis, Minnesota, United States, 55417

Minneapolis VA Medical Center
Minneapolis, Minnesota, United States, 55440

HealthPartners Research Foundation
Minneapolis, Minnesota, United States, 55455

University of Minnesota
New York Locations
New York, New York, United States, 10032

Columbia University Medical Center
North Carolina Locations
Durham, North Carolina, United States, 27710

Duke University
Pennsylvania Locations
Philadelphia, Pennsylvania, United States, 19140

Temple University
Pittsburgh, Pennsylvania, United States, 15232

University of Pittsburgh
Texas Locations
Houston, Texas, United States, 77030

Baylor College of Medicine
San Antonio, Texas, United States, 78229

University of Texas Health Sciences Center at San Antonio
Click to view interactive map

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies(https://clinicaltrials.gov/study-basics/learn-about-studies).
Eligibility Criteria
Description

Inclusion Criteria:

  • At least 10 pack-years of cigarette smoking (although a of nonsmoking controls is also being enrolled)
  • Self-designation of non-Hispanic white or African-American

Exclusion Criteria:

  • Other lung diseases (except for asthma in participants with COPD)
  • Pregnant
  • Cancer (other than skin cancer) in the 5 years prior to study entry
  • Received antibiotics for a COPD exacerbation in the 1 month prior to study entry
  • First- or second-degree relative of a previously enrolled study participant
Show less
Study Population

Particpants with COPD will include outpatient clinic patients, patients in registries, previous study participants, and COPD Foundation volunteers.

Participants without COPD will include spouses and friends of study participants with COPD and patients at primary care practices.

Ages Eligible for Study
45 Years to 80 Years (AdultOlder Adult )
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

/
Design Details
Observational Model : Cohort
Time Perspective: Prospective
Biospecimen Retention: Samples With DNA
Biospecimen Description: Genomic DNA, RNA, serum, and plasma will be collected and stored.

Groups and Interventions

Groups/Cohorts
Groups/Cohorts NHW COPD Participants
Non-Hispanic white participants with COPD
Groups/Cohorts NHW Control Group
Non-Hispanic white participants with normal spirometry (do not have COPD)
Groups/Cohorts AA COPD Participants
African-American participants with COPD
Groups/Cohorts AA Control Group
African-American participants with normal spirometry (do not have COPD)
Primary Outcome Measures
Outcome Measure Measure Description Time Frame
Forced expiratory volume in 1 second (FEV1) Measured at baseline
Emphysema, as shown on chest CT scan Measured at baseline
Airway wall thickness on chest CT scan Measured at baseline
COPD status (COPD participants versus control group participants) Measured at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.
Sponsor
Brigham and Women's Hospital
Collaborators
  • National Heart, Lung, and Blood Institute (NHLBI)
Investigators
  • Principal Investigator:James D. Crapo, MD,National Jewish Health
  • Principal Investigator:Edwin K. Silverman, MD, PhD,Brigham and Women's Hospital

Publications

From PubMed

These publications come from PubMed, a public database of scientific and medical articles. This list is automatically created by ClinicalTrials.gov Identifier (NCT Number), and these articles may or may not be about the study.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
2008-01-28
First Submitted that Met QC Criteria
2008-01-28
First Posted (Estimated)
2008-02-06
Study Record Updates
Last Update Submitted that met QC Criteria
2024-08-05
Last Update Posted
2024-08-06
Last Verified
2024-08

More Information

/

Keywords Provided by Edwin K. Silverman, Brigham and Women's Hospital
Additional Relevant MeSH Terms

Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
COPDGene phenotypic and genotypic data are available through dbGaP.